Merck Foundation and African First Ladies marking World Cancer Day 2023 through 110 scholarships of Oncology Fellowships in 25 countriesRead more Supporting women leaders and aspirants to unleash their potentialRead more Fake medicines kill almost 500,000 sub-Saharan Africans a year: United Nations Office on Drugs and Crime (UNODC) reportRead more Climate crisis and migration: Greta Thunberg supports International Organization for Migration (IOM) over ‘life and death’ issueRead more United Nations (UN) Convenes Lake Chad Countries, Amid Growing Regional CrisisRead more 11 Disruptive Startups Selected for Cohort 3 of the Africa Startup Initiative Program (ASIP) Accelerator Program powered by Startupbootcamp AfricaRead more Africa Data Centres breaks ground on new Sameer facility in NairobiRead more Coffee with a human face: A union that improves livelihoods for Ugandan farmersRead more Trends Predicted to drive the retail industry in 2023Read more Vantage Capital exits Pétro IvoireRead more

Pharma lobby blasts ‘stupid’ pandemic patent plans

show caption
World Trade Organization members are discussing broadening a temporary IP waiver for producing Covid vaccines./AFP
Print Friendly and PDF

Jan 12, 2023 - 11:27 AM

GENEVA, SWITZERLAND — Stripping patent protection from Covid-19 treatments is a “mind-bogglingly stupid” idea, the head of a leading pharmaceutical lobby said Wednesday, warning that the move would put industry innovation at risk.

Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), said the industry was still working on more effective Covid vaccines and treatments.

But Cueni said manufacturers would not risk ploughing investment into potential products if their intellectual property (IP) rights could be stripped away.

Cueni told reporters it would be “seriously dangerous” to move from voluntary knowledge-sharing seen during the pandemic to a “coercive” situation.

He added that when knowledge and technology is shared, generic manufacturers were still reliant on close support from the patent holders.

At the World Health Organization, plans are being drawn up for what could be a legally binding treaty on future pandemic preparedness.

Meanwhile, World Trade Organization members are discussing broadening a temporary IP waiver for producing Covid vaccines, agreed in June 2022, to include tests and treatments.

“That debate should simply have been closed,” Cueni said.

He said more than 800 potential Covid-19 treatments were being researched — and of approved treatments, around two-thirds were pre-existing medicines that companies had tested to see if they worked against Covid.

If the patent on the Covid part of any medicine is removed, there is “no way… to protect the original part”, he said.

“I have heard many companies say we would never have considered risking our core business and checking if it works” if they risked losing the protection that encouraged them to invest in at-risk research.

Therefore, an IP waiver “potentially undermining what worked so well in this pandemic is basically mind-bogglingly stupid”, Cueni said.

He also said proposals to waive patents on tests were “ludicrous” as there was no generic market for diagnostics.

Vaccine equity vow 

Cueni said IFPMA members were concerned about ensuring that what worked well in the Covid-19 response is not lost or compromised for future pandemic preparedness.

He said manufacturers needed fast, unhindered access to respond to emerging pathogens.

But he acknowledged that pharma firms needed to learn from “what didn’t work well — that is equitable roll-out” of vaccines.

“We need to make sure that dose-sharing is something we build in from day one,” he said.

Cueni said there needed to be greater geographic diversity in manufacturing, with most vaccines being produced only in the United States, Europe, China and India.

“Even if that works, you will still need to open borders and remove trade barriers,” he said, noting that supply chain problems could slow production.

And even then, “we need to work on country readiness because once we had not just sufficient supply of vaccines but an over-supply of vaccines, we still didn’t see the jabs getting into the arms of people”.

Cost claim 

With the pandemic now entering its fourth year, Cueni said major manufacturers were busy working on improved jabs and treatments.

He hoped that future vaccines would offer longer-lasting protection.

“It would be nice if one jab per year would suffice,” he said.

As for the profits made by the pharmaceutical industry during the pandemic, Cueni said: “When you look at how much Covid-19 cost the global economy, the cost of the treatments or the vaccines was just a tiny fraction of that.”

  • bio
  • twitter
  • facebook
  • latest posts

MAORANDCITIES.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.